Dai ichi Life Insurance Company Ltd Sells 1,412 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Dai ichi Life Insurance Company Ltd trimmed its position in United Therapeutics Co. (NASDAQ:UTHR) by 15.3% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 7,790 shares of the biotechnology company’s stock after selling 1,412 shares during the period. Dai ichi Life Insurance Company Ltd’s holdings in United Therapeutics were worth $2,792,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. LSV Asset Management grew its position in shares of United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after buying an additional 436,851 shares during the period. Swedbank AB acquired a new position in shares of United Therapeutics in the 1st quarter valued at $97,316,000. Assetmark Inc. boosted its position in shares of United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after purchasing an additional 152,249 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of United Therapeutics by 19.6% during the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock worth $178,972,000 after purchasing an additional 92,240 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its holdings in United Therapeutics by 49.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 276,531 shares of the biotechnology company’s stock valued at $88,089,000 after purchasing an additional 91,597 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of several analyst reports. The Goldman Sachs Group boosted their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. Wells Fargo & Company increased their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. Jefferies Financial Group lifted their target price on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, Bank of America cut their price objective on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $370.86.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 15,000 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $401.44, for a total transaction of $6,021,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $1,034,510.88. This represents a 85.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,485,785.60. This represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 117,227 shares of company stock valued at $43,671,320 in the last quarter. Company insiders own 11.90% of the company’s stock.

United Therapeutics Trading Up 2.3 %

UTHR stock opened at $377.00 on Wednesday. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The business’s 50 day simple moving average is $365.54 and its 200 day simple moving average is $333.04. The firm has a market capitalization of $16.83 billion, a PE ratio of 16.56, a PEG ratio of 1.07 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period last year, the business posted $5.38 earnings per share. As a group, sell-side analysts predict that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.